Pseudomonas Aeruginosa Vaccine: Novel Flagellin-based Vaccine

Serious Pseudomonas infections usually occur in people in the hospital and/or with weakened immune systems.  Infections of the blood, pneumonia, and infections following surgery can lead to severe illness and death in these people.  An effective vaccine will address the challenge of Pseudomonas based nosocomial infections and an aging baby-boomer population that is susceptible.  Additionally, a vaccine will address the growing problem of antibiotic resistance to Pseudomonas infection in this population.


Pseudomonas aeruginosa infections are a major cause of illness and death in patients with respiratory diseases such as cystic fibrosis, chronic obstructive pulmonary disease (COPD) and ventilator-associated pneumonia. Currently, there is no approved vaccine against Pseudomonas aeruginosa The Centers for Disease control has listed Pseudomonas infections as one of the 18 urgent drug resistance threats in the United States. 


A researcher at Wake Forest Baptist Medical Center and collaborators have developed a novel vaccine against Pseudomonas aeruginosa that is based on a fusion protein that combines flagellin with OprI and OprF antigens of Pseudomonas aeruginosa. The use of flagellin as an adjuvant results in a robust immune response to Pseudomonas aeruginosa against the key surface antigens in proven animal models, including mice and nonhuman primates, demonstrating effectiveness of the vaccine.   

Competitive Benefits

  • Potential to be the first approved vaccine against Pseudomonas aeruginosa
  • Generates better immune response than other Pseudomonas aeruginosa vaccines in development
  • Cost-effective, low dose formulation due to highly potent design
  • Simple and inexpensive to produce under good manufacturing practice conditions


  • Steven Mizel, PhD, Department of Microbiology and Immunology
  • Daniel J. Wozniak, PhD, Ohio State University Medical Center
  • Eric T. Weimer, PhD, Duke University Medical Center

Application Fields

Cystic fibrosis, chronic obstructive pulmonary disease, Pseudomonas aeruginosa respiratory infections, mechanical ventilator-associated pneumonia

Stage of Development

Researchers have established preclinical proof of concept in animal models. In published studies, protective immune response was documented in non-human primates and enhanced bacterial clearance without lung damage was established in mouse models.


Weimer ET et al. (2009). Immunization of young African green monkeys. Vaccine, 27(48), 6762-9.
Weimer ET et al. Enhanced Clearance of Nonmucoid Pseudomonas aeruginosa Infection Immunity. 2009;77(6):2356-66.


US 9,096,659; US 9,260,509;  US CON 14/989,585
EPO 10709779.2


Cystic fibrosis, chronic obstructive pulmonary disease, hospital-acquired pneumonia, ventilator-associated pneumonia, Pseudomonas aeruginosa, flagellin, fusion protein vaccine 

Licensing Contact

Peter Golikov
Licensing Director
Center for Technology Innovation & Commercialization

Reference #: 09-14

Back to Top